| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Carcinoma, Hepatocellular | 7 | 2025 | 163 | 1.910 |
Why?
|
| Liver Neoplasms | 7 | 2025 | 224 | 1.350 |
Why?
|
| Li-Fraumeni Syndrome | 3 | 2016 | 3 | 1.140 |
Why?
|
| Attitude to Computers | 1 | 2026 | 2 | 0.980 |
Why?
|
| Electronic Health Records | 1 | 2026 | 108 | 0.880 |
Why?
|
| Attitude of Health Personnel | 1 | 2026 | 231 | 0.820 |
Why?
|
| Tumor Suppressor Protein p53 | 4 | 2019 | 220 | 0.790 |
Why?
|
| Health Personnel | 1 | 2026 | 277 | 0.790 |
Why?
|
| Hepatitis C, Chronic | 2 | 2020 | 44 | 0.750 |
Why?
|
| Gastric Bypass | 1 | 2021 | 22 | 0.670 |
Why?
|
| Bariatric Surgery | 1 | 2021 | 23 | 0.670 |
Why?
|
| Weight Loss | 1 | 2021 | 137 | 0.630 |
Why?
|
| Gene Silencing | 2 | 2019 | 154 | 0.620 |
Why?
|
| Gastrointestinal Neoplasms | 1 | 2019 | 26 | 0.620 |
Why?
|
| Humans | 47 | 2026 | 43102 | 0.610 |
Why?
|
| Drug Monitoring | 1 | 2020 | 69 | 0.610 |
Why?
|
| Early Detection of Cancer | 1 | 2024 | 449 | 0.590 |
Why?
|
| Uterine Cervical Neoplasms | 1 | 2024 | 367 | 0.590 |
Why?
|
| Gene Expression Regulation, Neoplastic | 6 | 2020 | 968 | 0.580 |
Why?
|
| DNA Methylation | 2 | 2019 | 403 | 0.580 |
Why?
|
| Antihypertensive Agents | 1 | 2021 | 287 | 0.560 |
Why?
|
| Antiviral Agents | 1 | 2020 | 195 | 0.550 |
Why?
|
| Middle Aged | 22 | 2026 | 12222 | 0.520 |
Why?
|
| Intercellular Signaling Peptides and Proteins | 2 | 2016 | 100 | 0.510 |
Why?
|
| Female | 29 | 2026 | 24698 | 0.510 |
Why?
|
| Hepacivirus | 3 | 2018 | 74 | 0.500 |
Why?
|
| Adult | 20 | 2026 | 13872 | 0.500 |
Why?
|
| Health Knowledge, Attitudes, Practice | 1 | 2024 | 989 | 0.490 |
Why?
|
| Male | 26 | 2026 | 23409 | 0.460 |
Why?
|
| Neoplastic Stem Cells | 1 | 2016 | 99 | 0.460 |
Why?
|
| Ethiopia | 2 | 2026 | 16 | 0.450 |
Why?
|
| Hypertension | 1 | 2021 | 835 | 0.410 |
Why?
|
| Epigenesis, Genetic | 1 | 2016 | 291 | 0.410 |
Why?
|
| Obesity | 2 | 2021 | 1151 | 0.400 |
Why?
|
| Cohort Studies | 6 | 2025 | 1759 | 0.400 |
Why?
|
| Disease Progression | 5 | 2023 | 667 | 0.390 |
Why?
|
| Caveolin 1 | 1 | 2012 | 33 | 0.380 |
Why?
|
| Translocation, Genetic | 2 | 2016 | 40 | 0.370 |
Why?
|
| Gastrointestinal Diseases | 2 | 2023 | 51 | 0.360 |
Why?
|
| Retrospective Studies | 7 | 2025 | 2544 | 0.340 |
Why?
|
| Minority Groups | 1 | 2016 | 690 | 0.330 |
Why?
|
| Liver Cirrhosis | 3 | 2025 | 67 | 0.310 |
Why?
|
| HIV Infections | 2 | 2024 | 2586 | 0.310 |
Why?
|
| Gene Expression Profiling | 3 | 2026 | 704 | 0.300 |
Why?
|
| Colonic Polyps | 2 | 2020 | 71 | 0.300 |
Why?
|
| Breast Neoplasms | 3 | 2016 | 1723 | 0.280 |
Why?
|
| Cross-Sectional Studies | 3 | 2026 | 3156 | 0.280 |
Why?
|
| Prospective Studies | 7 | 2025 | 1600 | 0.280 |
Why?
|
| Janus Kinase 2 | 1 | 2008 | 36 | 0.270 |
Why?
|
| Aged | 12 | 2025 | 8214 | 0.270 |
Why?
|
| Mesoderm | 1 | 2008 | 73 | 0.270 |
Why?
|
| STAT5 Transcription Factor | 1 | 2008 | 49 | 0.270 |
Why?
|
| MicroRNAs | 2 | 2026 | 518 | 0.260 |
Why?
|
| Chromosomes, Human, Pair 15 | 1 | 2006 | 10 | 0.250 |
Why?
|
| Chromosomes, Human, Pair 11 | 1 | 2006 | 14 | 0.250 |
Why?
|
| Genes, p53 | 1 | 2006 | 27 | 0.250 |
Why?
|
| Computer Literacy | 1 | 2026 | 5 | 0.240 |
Why?
|
| Phosphopeptides | 1 | 2025 | 5 | 0.240 |
Why?
|
| Chromatography, High Pressure Liquid | 2 | 2010 | 465 | 0.240 |
Why?
|
| Risk Factors | 7 | 2025 | 3994 | 0.240 |
Why?
|
| Chromatography, Liquid | 2 | 2025 | 182 | 0.240 |
Why?
|
| Tumor Suppressor Proteins | 1 | 2008 | 223 | 0.240 |
Why?
|
| Down-Regulation | 2 | 2012 | 456 | 0.240 |
Why?
|
| RNA, Untranslated | 1 | 2026 | 50 | 0.230 |
Why?
|
| United States | 8 | 2025 | 5205 | 0.230 |
Why?
|
| Fatigue Syndrome, Chronic | 1 | 2025 | 8 | 0.220 |
Why?
|
| Tandem Mass Spectrometry | 2 | 2025 | 241 | 0.220 |
Why?
|
| Patient Participation | 1 | 2026 | 94 | 0.220 |
Why?
|
| Epithelial Cells | 1 | 2008 | 434 | 0.220 |
Why?
|
| Corneal Dystrophies, Hereditary | 2 | 2006 | 4 | 0.210 |
Why?
|
| Colorectal Neoplasms | 2 | 2020 | 512 | 0.210 |
Why?
|
| Liver Diseases | 1 | 2023 | 34 | 0.200 |
Why?
|
| Fibroblasts | 3 | 2016 | 281 | 0.200 |
Why?
|
| Azetidines | 1 | 2013 | 7 | 0.200 |
Why?
|
| Heptanoic Acids | 1 | 2013 | 12 | 0.200 |
Why?
|
| Microscopy, Confocal | 2 | 2006 | 224 | 0.200 |
Why?
|
| Age Factors | 3 | 2025 | 1154 | 0.200 |
Why?
|
| Blood Coagulation | 1 | 2023 | 29 | 0.200 |
Why?
|
| Pyrroles | 1 | 2013 | 72 | 0.190 |
Why?
|
| Viral Load | 2 | 2025 | 348 | 0.190 |
Why?
|
| Autoimmunity | 1 | 2023 | 58 | 0.190 |
Why?
|
| Sex Factors | 3 | 2025 | 1028 | 0.190 |
Why?
|
| Karyotyping | 2 | 2016 | 45 | 0.190 |
Why?
|
| Cell Line, Tumor | 4 | 2016 | 2676 | 0.190 |
Why?
|
| Community-Based Participatory Research | 1 | 2026 | 352 | 0.180 |
Why?
|
| Hepatitis C | 2 | 2018 | 139 | 0.180 |
Why?
|
| Incidence | 2 | 2025 | 1078 | 0.180 |
Why?
|
| Head and Neck Neoplasms | 1 | 2001 | 81 | 0.170 |
Why?
|
| Prevalence | 5 | 2025 | 1612 | 0.170 |
Why?
|
| Chromatography, Thin Layer | 1 | 2010 | 39 | 0.160 |
Why?
|
| Young Adult | 4 | 2025 | 5080 | 0.160 |
Why?
|
| Liver Function Tests | 1 | 2020 | 19 | 0.160 |
Why?
|
| Interferons | 1 | 2020 | 40 | 0.160 |
Why?
|
| Interleukins | 1 | 2020 | 40 | 0.160 |
Why?
|
| Uterine Diseases | 1 | 2019 | 5 | 0.160 |
Why?
|
| Polyps | 1 | 2019 | 9 | 0.160 |
Why?
|
| Carcinoma, Squamous Cell | 1 | 2001 | 186 | 0.160 |
Why?
|
| Signal Transduction | 2 | 2016 | 2157 | 0.160 |
Why?
|
| Aging | 1 | 2025 | 783 | 0.160 |
Why?
|
| beta Catenin | 1 | 2020 | 78 | 0.160 |
Why?
|
| Caco-2 Cells | 1 | 2019 | 64 | 0.160 |
Why?
|
| Hep G2 Cells | 1 | 2019 | 63 | 0.160 |
Why?
|
| Crohn Disease | 1 | 2020 | 71 | 0.150 |
Why?
|
| Colitis, Ulcerative | 1 | 2020 | 70 | 0.150 |
Why?
|
| Liver | 2 | 2019 | 511 | 0.150 |
Why?
|
| Carrier Proteins | 1 | 2001 | 321 | 0.150 |
Why?
|
| Colitis | 1 | 2020 | 71 | 0.150 |
Why?
|
| Metabolome | 1 | 2019 | 51 | 0.150 |
Why?
|
| Gene Regulatory Networks | 1 | 2020 | 149 | 0.150 |
Why?
|
| Patient Acceptance of Health Care | 1 | 2024 | 497 | 0.150 |
Why?
|
| Alleles | 1 | 2020 | 352 | 0.150 |
Why?
|
| Inflammatory Bowel Diseases | 1 | 2020 | 104 | 0.150 |
Why?
|
| Metabolomics | 1 | 2019 | 95 | 0.140 |
Why?
|
| Indoles | 1 | 2010 | 187 | 0.140 |
Why?
|
| Biomedical Research | 1 | 2023 | 502 | 0.140 |
Why?
|
| Poly(ADP-ribose) Polymerases | 3 | 2003 | 79 | 0.140 |
Why?
|
| Genotype | 1 | 2020 | 800 | 0.130 |
Why?
|
| Severity of Illness Index | 1 | 2020 | 719 | 0.130 |
Why?
|
| Mutation | 2 | 2006 | 1177 | 0.130 |
Why?
|
| Galactose | 1 | 1996 | 9 | 0.130 |
Why?
|
| 2-Pyridinylmethylsulfinylbenzimidazoles | 1 | 2006 | 5 | 0.120 |
Why?
|
| Omeprazole | 1 | 2006 | 7 | 0.120 |
Why?
|
| Proton Pump Inhibitors | 1 | 2006 | 16 | 0.120 |
Why?
|
| Fatty Liver | 1 | 2017 | 77 | 0.120 |
Why?
|
| Treatment Outcome | 1 | 2021 | 1604 | 0.120 |
Why?
|
| Calcium-Binding Proteins | 1 | 2016 | 81 | 0.120 |
Why?
|
| Germ-Line Mutation | 1 | 2016 | 75 | 0.120 |
Why?
|
| Body Mass Index | 1 | 2020 | 925 | 0.120 |
Why?
|
| Polymorphism, Single Nucleotide | 1 | 2020 | 863 | 0.120 |
Why?
|
| Cell Proliferation | 2 | 2019 | 1455 | 0.110 |
Why?
|
| RNA, Messenger | 1 | 2020 | 1271 | 0.110 |
Why?
|
| DNA, Mitochondrial | 1 | 1996 | 191 | 0.110 |
Why?
|
| Pyridines | 1 | 2016 | 139 | 0.110 |
Why?
|
| Adaptor Proteins, Signal Transducing | 1 | 2016 | 213 | 0.110 |
Why?
|
| Cell Nucleus | 1 | 1996 | 383 | 0.110 |
Why?
|
| Models, Biological | 1 | 2018 | 712 | 0.110 |
Why?
|
| RNA, Small Interfering | 1 | 2016 | 436 | 0.110 |
Why?
|
| Promoter Regions, Genetic | 1 | 2016 | 526 | 0.100 |
Why?
|
| Health Status Disparities | 1 | 2020 | 719 | 0.100 |
Why?
|
| Cell Line | 4 | 2016 | 1410 | 0.100 |
Why?
|
| Phenotype | 1 | 2016 | 780 | 0.100 |
Why?
|
| DNA | 1 | 1996 | 592 | 0.100 |
Why?
|
| Mitochondria | 1 | 1996 | 523 | 0.100 |
Why?
|
| Feedback, Physiological | 1 | 2012 | 32 | 0.100 |
Why?
|
| Cyclin-Dependent Kinase Inhibitor p21 | 1 | 2012 | 56 | 0.090 |
Why?
|
| Gene Expression | 3 | 2012 | 701 | 0.090 |
Why?
|
| Case-Control Studies | 2 | 2026 | 1285 | 0.090 |
Why?
|
| Aged, 80 and over | 3 | 2025 | 2853 | 0.090 |
Why?
|
| Benzothiazoles | 1 | 2012 | 26 | 0.090 |
Why?
|
| Benzofurans | 1 | 2012 | 22 | 0.090 |
Why?
|
| Benzimidazoles | 1 | 2012 | 43 | 0.090 |
Why?
|
| Longitudinal Studies | 2 | 2025 | 1063 | 0.090 |
Why?
|
| Angiogenesis Inhibitors | 1 | 2012 | 62 | 0.090 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 1 | 2012 | 310 | 0.090 |
Why?
|
| Cell Cycle | 1 | 2012 | 346 | 0.080 |
Why?
|
| Puerto Rico | 2 | 2025 | 1413 | 0.080 |
Why?
|
| Up-Regulation | 1 | 2012 | 536 | 0.080 |
Why?
|
| Adolescent | 3 | 2025 | 6081 | 0.080 |
Why?
|
| Drug Stability | 2 | 2010 | 129 | 0.070 |
Why?
|
| Cell Line, Transformed | 1 | 2008 | 95 | 0.070 |
Why?
|
| Ophthalmoscopes | 1 | 2006 | 2 | 0.060 |
Why?
|
| Risk Assessment | 2 | 2020 | 863 | 0.060 |
Why?
|
| Chromosome Banding | 1 | 2006 | 6 | 0.060 |
Why?
|
| Homozygote | 1 | 2006 | 77 | 0.060 |
Why?
|
| In Situ Hybridization, Fluorescence | 1 | 2006 | 58 | 0.060 |
Why?
|
| Heterozygote | 1 | 2006 | 110 | 0.060 |
Why?
|
| alpha-Fetoproteins | 1 | 2025 | 32 | 0.060 |
Why?
|
| Logistic Models | 2 | 2020 | 1009 | 0.060 |
Why?
|
| DNA Fragmentation | 2 | 2002 | 98 | 0.060 |
Why?
|
| Neuroblastoma | 1 | 2006 | 136 | 0.060 |
Why?
|
| Independent Living | 1 | 2025 | 47 | 0.060 |
Why?
|
| Cell Differentiation | 1 | 2008 | 638 | 0.050 |
Why?
|
| Proteome | 1 | 2025 | 152 | 0.050 |
Why?
|
| Vomiting | 1 | 2023 | 14 | 0.050 |
Why?
|
| Tumor Cells, Cultured | 2 | 2002 | 508 | 0.050 |
Why?
|
| Intracellular Signaling Peptides and Proteins | 2 | 2002 | 200 | 0.050 |
Why?
|
| Reproducibility of Results | 2 | 2013 | 1081 | 0.050 |
Why?
|
| Community-Institutional Relations | 1 | 2026 | 219 | 0.050 |
Why?
|
| Multicenter Studies as Topic | 1 | 2023 | 61 | 0.050 |
Why?
|
| Proteomics | 1 | 2025 | 378 | 0.050 |
Why?
|
| Pilot Projects | 1 | 2026 | 760 | 0.050 |
Why?
|
| Etoposide | 1 | 2002 | 21 | 0.050 |
Why?
|
| Fatigue | 1 | 2023 | 100 | 0.050 |
Why?
|
| Troponin | 1 | 2022 | 17 | 0.050 |
Why?
|
| Endodeoxyribonucleases | 1 | 2002 | 28 | 0.050 |
Why?
|
| Proteins | 2 | 2002 | 382 | 0.050 |
Why?
|
| Osteosarcoma | 1 | 2002 | 30 | 0.050 |
Why?
|
| Bone Neoplasms | 1 | 2002 | 49 | 0.050 |
Why?
|
| Poverty | 1 | 2025 | 400 | 0.040 |
Why?
|
| Ferritins | 1 | 2022 | 63 | 0.040 |
Why?
|
| Diarrhea | 1 | 2022 | 95 | 0.040 |
Why?
|
| Adenoviridae | 1 | 2001 | 62 | 0.040 |
Why?
|
| Neoplasm Transplantation | 1 | 2001 | 129 | 0.040 |
Why?
|
| Blotting, Northern | 1 | 2001 | 150 | 0.040 |
Why?
|
| Laminin | 1 | 2001 | 58 | 0.040 |
Why?
|
| Proteoglycans | 1 | 2001 | 49 | 0.040 |
Why?
|
| Apoptosis | 2 | 2016 | 1568 | 0.040 |
Why?
|
| Drug Combinations | 1 | 2001 | 104 | 0.040 |
Why?
|
| DNA Primers | 1 | 2001 | 294 | 0.040 |
Why?
|
| Follow-Up Studies | 1 | 2023 | 1067 | 0.040 |
Why?
|
| Cell Division | 1 | 2001 | 311 | 0.040 |
Why?
|
| Latin America | 1 | 2020 | 55 | 0.040 |
Why?
|
| Antineoplastic Agents, Phytogenic | 1 | 2002 | 134 | 0.040 |
Why?
|
| Collagen | 1 | 2001 | 181 | 0.040 |
Why?
|
| Densitometry | 1 | 2010 | 16 | 0.040 |
Why?
|
| Neovascularization, Pathologic | 1 | 2001 | 139 | 0.040 |
Why?
|
| Mice, Nude | 1 | 2001 | 408 | 0.040 |
Why?
|
| Spectrophotometry, Ultraviolet | 1 | 2010 | 104 | 0.040 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 1 | 2001 | 652 | 0.040 |
Why?
|
| Quality of Life | 1 | 2025 | 616 | 0.040 |
Why?
|
| Limit of Detection | 1 | 2010 | 94 | 0.040 |
Why?
|
| Lung | 1 | 2003 | 492 | 0.040 |
Why?
|
| Tumor Necrosis Factor-alpha | 1 | 2002 | 384 | 0.040 |
Why?
|
| Colonoscopy | 1 | 2020 | 122 | 0.040 |
Why?
|
| RNA | 1 | 2001 | 266 | 0.040 |
Why?
|
| Corneal Stroma | 1 | 1999 | 6 | 0.040 |
Why?
|
| Endothelium, Corneal | 1 | 1999 | 8 | 0.040 |
Why?
|
| Gas Chromatography-Mass Spectrometry | 1 | 2019 | 83 | 0.040 |
Why?
|
| Stromal Cells | 1 | 1999 | 55 | 0.040 |
Why?
|
| Asthma | 1 | 2003 | 416 | 0.040 |
Why?
|
| Odds Ratio | 1 | 2020 | 587 | 0.040 |
Why?
|
| Hospitalization | 1 | 2022 | 485 | 0.040 |
Why?
|
| Comorbidity | 1 | 2020 | 737 | 0.030 |
Why?
|
| Lipid Metabolism | 1 | 2019 | 148 | 0.030 |
Why?
|
| Prognosis | 1 | 2020 | 861 | 0.030 |
Why?
|
| Anti-Ulcer Agents | 1 | 2006 | 7 | 0.030 |
Why?
|
| Cricetinae | 1 | 1996 | 241 | 0.030 |
Why?
|
| Acids | 1 | 2006 | 19 | 0.030 |
Why?
|
| Mice | 3 | 2003 | 6644 | 0.030 |
Why?
|
| Chemistry, Pharmaceutical | 1 | 2006 | 97 | 0.030 |
Why?
|
| Animals | 4 | 2003 | 16992 | 0.030 |
Why?
|
| Multivariate Analysis | 1 | 2017 | 638 | 0.030 |
Why?
|
| Body Weight | 1 | 2017 | 429 | 0.030 |
Why?
|
| Diabetes Mellitus | 1 | 2019 | 539 | 0.030 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2016 | 1124 | 0.020 |
Why?
|
| Smoking | 1 | 2019 | 1024 | 0.020 |
Why?
|
| Spectrophotometry, Infrared | 1 | 2012 | 31 | 0.020 |
Why?
|
| Indicators and Reagents | 1 | 2012 | 61 | 0.020 |
Why?
|
| Cell Movement | 1 | 2016 | 655 | 0.020 |
Why?
|
| Caspases | 2 | 2002 | 148 | 0.020 |
Why?
|
| Drug Screening Assays, Antitumor | 1 | 2012 | 157 | 0.020 |
Why?
|
| Caspase 3 | 2 | 2002 | 227 | 0.020 |
Why?
|
| Pyrazoles | 1 | 2012 | 103 | 0.020 |
Why?
|
| Enzyme Activation | 2 | 2002 | 462 | 0.020 |
Why?
|
| Transfection | 2 | 2002 | 532 | 0.020 |
Why?
|
| Apoptosis Regulatory Proteins | 2 | 2002 | 161 | 0.020 |
Why?
|
| Magnetic Resonance Spectroscopy | 1 | 2012 | 301 | 0.020 |
Why?
|
| Drug Design | 1 | 2012 | 186 | 0.020 |
Why?
|
| Structure-Activity Relationship | 1 | 2012 | 506 | 0.020 |
Why?
|
| Endothelial Cells | 1 | 2012 | 329 | 0.020 |
Why?
|
| Antineoplastic Agents | 1 | 2016 | 1019 | 0.020 |
Why?
|
| Ophthalmoscopy | 1 | 2006 | 12 | 0.020 |
Why?
|
| Equipment Failure Analysis | 1 | 2006 | 45 | 0.020 |
Why?
|
| Equipment Design | 1 | 2006 | 145 | 0.020 |
Why?
|
| Sensitivity and Specificity | 1 | 2006 | 611 | 0.010 |
Why?
|
| Ovalbumin | 1 | 2003 | 47 | 0.010 |
Why?
|
| Oxidants | 1 | 2003 | 42 | 0.010 |
Why?
|
| L-Lactate Dehydrogenase | 1 | 2003 | 64 | 0.010 |
Why?
|
| Interleukin-8 | 1 | 2003 | 74 | 0.010 |
Why?
|
| Staurosporine | 1 | 2002 | 38 | 0.010 |
Why?
|
| Allergens | 1 | 2003 | 65 | 0.010 |
Why?
|
| Nucleosomes | 1 | 2002 | 30 | 0.010 |
Why?
|
| Benzamides | 1 | 2003 | 81 | 0.010 |
Why?
|
| Nitric Oxide Synthase | 1 | 2003 | 135 | 0.010 |
Why?
|
| Transcriptional Activation | 1 | 2003 | 173 | 0.010 |
Why?
|
| Cytochrome c Group | 1 | 2002 | 14 | 0.010 |
Why?
|
| Hydrogen Peroxide | 1 | 2003 | 190 | 0.010 |
Why?
|
| Deoxyribonucleases | 1 | 2002 | 27 | 0.010 |
Why?
|
| Mice, Mutant Strains | 1 | 2002 | 83 | 0.010 |
Why?
|
| NAD | 1 | 2002 | 45 | 0.010 |
Why?
|
| Protein Subunits | 1 | 2002 | 93 | 0.010 |
Why?
|
| Adenosine Triphosphate | 1 | 2002 | 206 | 0.010 |
Why?
|
| Recombinant Proteins | 1 | 2002 | 518 | 0.010 |
Why?
|
| Enzyme Inhibitors | 1 | 2003 | 458 | 0.010 |
Why?
|
| NF-kappa B | 1 | 2003 | 358 | 0.010 |
Why?
|
| Mice, Knockout | 1 | 2003 | 1035 | 0.010 |
Why?
|
| Calcium | 1 | 2002 | 491 | 0.010 |
Why?
|
| Cells, Cultured | 1 | 2002 | 1621 | 0.010 |
Why?
|
| Mice, Inbred C57BL | 1 | 2003 | 1869 | 0.010 |
Why?
|
| Inflammation | 1 | 2003 | 758 | 0.010 |
Why?
|